Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence to accelerate patient access to...
Hence then, the article about sun pharma to acquire checkpoint therapeutics was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Sun Pharma to Acquire Checkpoint Therapeutics )
Also on site :
- From collapse fears to resilience: How Russia reshaped its economy by the end of 2025
- Russian MOD shows map of Ukrainian drone attack on Putin’s residence
- Advantech Unveils Next-Generation Edge AI Compute Solutions Powered by Qualcomm Dragonwing IQ-X Series